Hepatology experts recently convened for a Cleveland Clinic webcast to discuss whether surgical treatments can cure metabolic dysfunction-associated steatohepatitis (MASH) [1].
The discussion is critical because MASH represents a severe form of fatty liver disease that often resists standard medical management. Determining if surgical intervention can provide a definitive cure could fundamentally change the treatment pathway for patients with advanced gastrointestinal disorders [2].
Dr. Sobia Laique of the Cleveland Clinic moderated the roundtable, which included Dr. Naim Alkhouri of Summit Clinical and other specialists in the field [1]. The group focused on innovative medical and surgical approaches to address the disease's progression [2].
During the session, the panel evaluated the efficacy of various procedures in reversing liver damage. While the experts explored the potential for surgery to mitigate the effects of MASH, they did not confirm a definitive surgical cure for the condition [1].
The roundtable served as a platform to share updates on the current state of hepatology. The experts examined how surgical options compare to emerging pharmacological treatments in managing liver inflammation, and scarring [2].
Because the disease often involves complex metabolic dysfunction, the specialists emphasized the need for a multidisciplinary approach. The conversation highlighted the gap between current surgical capabilities and the goal of total disease eradication [1].
“Hepatology experts recently convened for a Cleveland Clinic webcast to discuss whether surgical treatments can cure MASH.”
The lack of a confirmed surgical cure during this expert roundtable suggests that MASH remains a complex challenge that cannot be solved by surgery alone. This underscores the ongoing necessity for integrated medical strategies that combine lifestyle changes, medication, and potential surgical interventions to manage the disease.
